Phase III
Esperion today announced that the final Phase 3 results from Study 3 (1002-046, also known as CLEAR Serenity) were presented at the American Heart Association (AHA) Scientific Sessions in Chicago.
It is estimated that 2.5 percent of all children in the U.S. might have a peanut allergy. Since 2010, according to the America College of Allergy, Asthma and Immunology, incidence of peanut allergies in children had risen 21 percent in the U.S.
An ovarian cancer treatment co-developed by Germany’s Merck KGaA and Pfizer failed to meet endpoints for overall survival and progression-free survival in a Phase III trial.
AstraZeneca is attempting to find encouraging news in the failure of its MYSTIC clinical trial, but it doesn’t look good.
AbbVie presented additional data from two Phase III clinical trials in women with uterine fibroids. In a big news week for the company, what else is AbbVie up to?
Chicago-based AbbVie just announced new data for its Mavyret (glecaprevir/pibrentasvir), a pan-genotypic treatment for chronic HCV in treatment-naive patients with compensated cirrhosis.
New Phase 3 Trial of Tonmya® for the treatment of PTSD to Commence First Quarter 2019
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
Met primary endpoint of Early Clinical Response at 96 hours after the first dose
Phase 3 Program Achieved Safety and Tolerability Objectives
PRESS RELEASES